Physical principles of monopolar vs bipolar RF
The sacroiliac joint complex is innervated by the posterior sacral network (PSN), which includes the lateral branches of the S1–S3 posterior rami with variable contributions from S4 and the L5 dorsal ramus. Interruption of these sensory pathways using image-guided radiofrequency ablation (RFA) can reduce pain and disability in appropriately selected patients with sacroiliac joint complex pain. The fundamental goal of both conventional monopolar and bipolar techniques is to create thermal lesions that denervate these lateral branches while minimizing collateral tissue injury.
Conventional, or monopolar, sacroiliac RFA typically uses a single active electrode and a distant dispersive ground pad to complete the circuit. Lesion size is therefore constrained around the active tip and is influenced by factors such as electrode gauge, active tip length, temperature, and duration of lesioning. In the COBRA-SIJ protocol, conventional sacroiliac joint RFA (C-SIJRFA) uses a 22-gauge cannula with a 5-mm exposed tip, positioned periforaminally 3–5 mm lateral to the posterior sacral foraminal apertures at S1–S3, with monopolar lesions performed for 90 seconds at 80°C at each site. This periforaminal approach aims to capture the lateral branches as they exit the dorsal sacral foramina.
In contrast, bipolar RFA uses two or more closely spaced active electrodes between which current flows, generating a larger and more continuous lesion between the electrodes. Cadaveric work summarized in the COBRA-SIJ materials indicates that targeting the PSN with a large bipolar strip lesion can achieve greater than 95% neural capture, whereas a conventional monopolar periforaminal technique may capture as little as 2.5% of the PSN. Nimbus, a multi-tined bipolar RFA probe, is designed to create such large strip lesions along the lateral sacral crest, making it an attractive option for more complete PSN ablation.
The COBRA-SIJ protocol operationalizes these physical principles by positioning Nimbus electrodes along the lateral sacral crest lateral to the inflection points of the S1–S3 lateral foraminal walls, maintaining a craniocaudal line with an interelectrode distance of no more than 15 mm. Lesions in the bipolar Nimbus group (N-SIJRFA) are performed at 85°C for 180 seconds at each bipolar site, with an additional monopolar lesion at the L5 dorsal ramus at 80°C for 90 seconds in both treatment arms to control for potential L5/S1 facet-mediated pain. This design reflects the underlying hypothesis that a larger, continuous bipolar strip lesion will provide more complete PSN denervation than multiple smaller monopolar periforaminal lesions.
Beyond the COBRA-SIJ trial, a broader evidence review on radiofrequency neurotomy for sacral lateral branch pain emphasizes that bipolar or cooled RF is ideal when the objective is to ensure capture of the lateral branches with a larger lesion, whereas monopolar RF can be effective but often requires multiple passes or periforaminal techniques to approximate similar lesion coverage. This reinforces the conceptual distinction between monopolar and bipolar approaches: monopolar RF relies on multiple discrete lesions to approximate coverage, while bipolar RF is engineered to create a larger, more contiguous lesion field over the target neural network.
Study design of the COBRA-SIJ trial
The COBRA-SIJ study (“Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blind, Randomized, Comparative Trial”) is a double-blinded randomized controlled trial designed to compare Nimbus-based bipolar RFA (N-SIJRFA) with conventional monopolar periforaminal RFA (C-SIJRFA) for sacroiliac joint complex pain. The central hypothesis is that N-SIJRFA will be more effective than C-SIJRFA in improving pain and function at 3, 6, 12, 18, and 24 months. This trial is positioned to address a major evidence gap, as prior literature had not included a prospective randomized comparison of these two commonly used techniques.
Participants are adults aged 18–90 years with at least three months of low back pain attributed to the sacroiliac joint complex, who have not responded to at least three months of conservative treatment. Eligibility requires a 7-day average Numeric Pain Rating Scale (NPRS) score of at least 4/10 at baseline and at least 50% pain relief following either a combination of fluoroscopically guided intra-articular sacroiliac joint injection plus PSN block, or dual PSN blocks. These diagnostic procedures reflect standard practice for confirming sacroiliac joint complex pain and are intended to enrich the study population for patients likely to respond to PSN ablation.
Key exclusion criteria include prior sacroiliac joint fusion, prior sacroiliac RFA, symptomatic hip osteoarthritis, active lumbar radicular pain, evidence of hardware loosening after lumbar or lumbosacral fusion, presence of pacemaker or neurostimulator, chronic widespread pain or somatoform disorders, high-dose opioid use (>50 mg morphine-equivalent per day), active infection or recent antibiotic treatment, and other conditions associated with significant functional disability or confounding psychosocial factors. These criteria are intended to reduce diagnostic uncertainty and minimize confounding from other pain generators or systemic conditions.
Randomization assigns participants to either N-SIJRFA or C-SIJRFA, with both participants and outcome assessors blinded to treatment allocation. In the Nimbus group, electrodes are placed along the lateral sacral crest to create a continuous bipolar strip lesion, with lesions performed at 85°C for 180 seconds at each site, plus a monopolar lesion at the L5 dorsal ramus. In the conventional group, monopolar electrodes are positioned periforaminally at S1–S3 using standardized “clock-face” positions relative to the posterior sacral foraminal apertures, with lesions at 80°C for 90 seconds at each site, and a similar L5 dorsal ramus lesion. Conscious sedation with midazolam and fentanyl may be used, with continuous cardiopulmonary monitoring.
The primary outcome is the proportion of participants achieving at least 50% reduction in NPRS pain score at 3 months. Secondary outcomes include the proportion with ≥50% pain relief at 6, 12, 18, and 24 months; time to failure (defined as return of ≥50% index pain or repeat sacroiliac RFA); the proportion achieving ≥15-point reduction in Oswestry Disability Index (ODI); clinically significant improvement in EQ-5D (≥0.03 increase); patient global impression of change; improvement in pain-related sleep disturbance; adverse event rates; fluoroscopy time; and subsequent interventional health care utilization including repeat RFA, sacroiliac injections, and sacroiliac fusion. A press release notes that the trial aims to enroll and randomize 116 patients with follow-up at 3, 6, 12, 18, and 24 months.
Patient outcomes at 3, 6, 12, and 24 months
The COBRA-SIJ protocol specifies a structured follow-up schedule at 3, 6, 12, 18, and 24 months after the index RFA procedure, with the 3-month time point designated for assessment of the primary outcome. At each of these visits, NPRS pain scores, ODI, EQ-5D, and other patient-reported outcomes are collected to evaluate both short- and longer-term effects of Nimbus-based bipolar versus conventional monopolar RFA on sacroiliac joint complex pain. The trial is designed to determine whether the hypothesized advantages of more complete PSN capture with bipolar strip lesions translate into superior clinical outcomes over two years.
At 3 months, the primary endpoint is the proportion of participants in each arm who achieve at least 50% reduction in NPRS pain score compared with baseline. This threshold is consistent with prior sacroiliac RFA literature, where a systematic review estimated that 32–89% of patients achieve at least 50% pain relief for six months after PSN ablation, albeit with heterogeneous techniques and technologies. By using a standardized protocol and randomized design, COBRA-SIJ aims to provide more definitive comparative data at this early time point.
At 6, 12, 18, and 24 months, the same ≥50% NPRS pain reduction criterion is used to assess sustained response. Time to failure is defined as either return of ≥50% of index pain or the need for repeat sacroiliac RFA, allowing for survival analysis of durability of benefit in each group. The protocol also anticipates that repeat procedures may be performed after the 6-month outcome collection if the treating physician deems them indicated and the participant has reported greater than 50% improvement from baseline at 3 and 6 months, with the same randomized technique repeated and blinding maintained.
In addition to pain intensity, the trial collects ODI, EQ-5D, and other measures at each follow-up to characterize functional status, health-related quality of life, and patient global impression of change over time. The central hypothesis is that Nimbus-based bipolar RFA will yield higher proportions of responders and more durable improvements in these domains at 3, 6, 12, 18, and 24 months compared with conventional monopolar periforaminal RFA. However, the protocol documents and associated materials describe the planned design and endpoints rather than reporting completed outcome data, reflecting the ongoing nature of the trial.
The broader evidence base summarized in the COBRA-SIJ background highlights that technologies capable of creating larger lesions, including bipolar and cooled RF, have been associated with higher probabilities of clinical success in some studies, although direct randomized comparisons have been lacking. The COBRA-SIJ follow-up framework is therefore structured to detect potential differences in both early and sustained response between bipolar and conventional techniques, with particular attention to the durability of pain relief and the need for repeat interventions over a two-year horizon.
Pain reduction, disability scores and EQ-5D
Pain intensity is quantified in COBRA-SIJ using the Numeric Pain Rating Scale (NPRS), with the primary endpoint defined as the proportion of participants achieving at least 50% reduction in NPRS at 3 months. Secondary analyses extend this ≥50% pain relief threshold to 6, 12, 18, and 24 months. This dichotomous responder definition aligns with prior sacroiliac RFA literature and is intended to provide a clinically meaningful measure of pain reduction that can be directly compared between Nimbus-based bipolar and conventional monopolar techniques.
Functional disability is assessed using the Oswestry Disability Index (ODI). One of the key secondary outcomes is the proportion of participants achieving at least a 15-point reduction in ODI at 3, 6, 12, 18, and 24 months after treatment. This threshold is used as a marker of clinically significant functional improvement. By evaluating both pain and disability, the trial aims to determine whether any differences in lesion geometry and neural capture between bipolar and monopolar RFA translate into meaningful gains in daily function and activity tolerance.
Health-related quality of life is measured using the EuroQol 5 Dimensions (EQ-5D) instrument. The COBRA-SIJ protocol defines a clinically significant improvement in EQ-5D as an increase of at least 0.03 in the index score, and one of the secondary outcomes is the proportion of patients in each arm achieving this threshold at 3, 6, 12, 18, and 24 months. This allows for a standardized comparison of the impact of Nimbus-based bipolar versus conventional monopolar RFA on broader aspects of health status beyond pain and disability alone.
Additional patient-centered outcomes include the Patient Global Impression of Change (PGIC), where the proportions of participants reporting being “improved” or “much improved” are compared between groups at each follow-up, and the Pain and Sleep Questionnaire (PSQ-3) to assess changes in pain-related sleep disturbance. Baseline values for NPRS, ODI, EQ-5D, PSQ-3, and other measures are collected at the initial visit, along with demographic and clinical characteristics, to support adjusted analyses and exploration of predictors of response. Together, these instruments provide a comprehensive framework for evaluating the multidimensional impact of sacroiliac RFA using bipolar versus conventional techniques.
Outside the COBRA-SIJ trial, an evidence-based review of radiofrequency neurotomy for sacral lateral branch pain notes that bipolar RF has been associated with improvements in pain, physical function, and spinal mobility in certain patient populations, and that both unipolar and bipolar RF techniques can be clinically effective when appropriately applied. However, heterogeneity in techniques, parameters, and patient selection across studies has limited the ability to draw firm comparative conclusions, underscoring the importance of the standardized outcome framework adopted in COBRA-SIJ.
Adverse events and repeat procedures
The COBRA-SIJ protocol prospectively tracks adverse events related to sacroiliac RFA, including cardiopulmonary compromise, neurologic deficits, numbness, ataxia, vasovagal syncope, and neuritis, as well as infection and other complications. The informed consent document for the trial lists expected side effects of Nimbus and conventional RFA such as temporary pain or discomfort around the treated area, self-limited muscle soreness or spasm, minor bleeding, temporary nerve pain, post-procedural neuritis or localized numbness, nausea, and vasovagal responses. Potential complications include infection, major bleeding, motor nerve damage resulting in weakness, and allergic reactions to medications used.
Adverse event monitoring is integrated into procedural and follow-up data collection. Procedural records capture sedation use, presence of trainees, procedure time, absorbed radiation dose, and immediate adverse events. Follow-up assessments provide opportunities to identify delayed complications such as neuritis, persistent numbness, or new neurologic deficits. The protocol also acknowledges the possibility of unforeseeable risks, consistent with standard practice in interventional pain trials.
Repeat RFA procedures are permitted after the 6-month outcome collection under specific conditions. The treating physician must judge that repeat treatment is indicated, the participant must agree, and the participant must have reported greater than 50% improvement from baseline NPRS at both 3 and 6 months. When these criteria are met, the same technique to which the participant was originally randomized (Nimbus-based bipolar or conventional monopolar) is repeated, and the participant remains blinded to allocation; cross-over is not offered.
The trial plans a survival analysis to illustrate the proportion of patients in each group who maintain treatment success—defined as at least 50% pain relief—without requiring further interventional health care utilization such as repeat RFA, sacroiliac injection, or sacroiliac fusion. Secondary outcomes explicitly include rates of subsequent interventional utilization, including repeat Nimbus or conventional RFA, sacroiliac injections, and sacroiliac fusion, as well as rates of adverse effects including infection. These analyses are intended to capture both safety and durability of effect for bipolar versus conventional techniques over the 24-month follow-up.
More broadly, consensus and review documents on sacral lateral branch radiofrequency neurotomy emphasize standard contraindications such as sacral fracture, tumor, radiculopathy, infection, and coagulopathy, and recommend careful patient selection with diagnostic blocks prior to RF. The COBRA-SIJ inclusion and exclusion criteria, along with its structured adverse event and repeat-procedure monitoring, are aligned with these principles and are designed to provide robust comparative safety data for Nimbus-based bipolar and conventional monopolar sacroiliac RFA.
Summary of clinical recommendations
The COBRA-SIJ trial is designed to address a critical gap in the evidence base by directly comparing Nimbus-based bipolar strip-lesion RFA with conventional monopolar periforaminal RFA for sacroiliac joint complex pain in a double-blinded randomized controlled framework. Cadaveric and anatomical data suggest that bipolar strip lesions along the lateral sacral crest can achieve substantially higher PSN neural capture than conventional monopolar periforaminal lesions, providing a strong mechanistic rationale for evaluating potential clinical advantages of the Nimbus technique.
The protocol emphasizes rigorous patient selection based on clinical assessment, imaging, and response to fluoroscopically guided diagnostic blocks, with inclusion restricted to adults with chronic sacroiliac joint complex pain who have failed conservative therapy and demonstrate at least 50% pain relief from prognostic PSN or intra-articular sacroiliac injections. This approach is consistent with broader recommendations that diagnostic lateral sacral branch blocks are important for identifying appropriate candidates for sacral lateral branch radiofrequency neurotomy.
From a procedural standpoint, the COBRA-SIJ materials and related evidence-based reviews highlight that bipolar or cooled RF is preferred when the goal is to maximize lesion size and ensure capture of the lateral branches, whereas monopolar RF can be effective but may require multiple passes or periforaminal techniques to achieve adequate coverage. In the Nimbus protocol, electrodes are placed to create a continuous strip lesion along the lateral sacral crest with standardized temperature and duration parameters, while the conventional arm uses a well-described periforaminal monopolar technique with defined “clock-face” positions at S1–S3.
Clinically, the COBRA-SIJ outcome framework—centered on ≥50% NPRS pain reduction, ≥15-point ODI improvement, and ≥0.03 EQ-5D gain at 3, 6, 12, 18, and 24 months, along with PGIC, sleep disturbance, adverse events, and subsequent interventional utilization—provides a comprehensive basis for future evidence-based recommendations on technique selection for sacroiliac RFA. Current protocol and background documents underscore the potential for Nimbus-based bipolar RFA to improve pain and function relative to conventional monopolar RFA, but definitive comparative clinical recommendations await full reporting of trial results.
Until such results are available, practice patterns may reasonably be informed by the mechanistic advantages of larger bipolar lesions for PSN capture, the feasibility and safety profile of both Nimbus and conventional techniques as outlined in the COBRA-SIJ materials, and existing evidence that both unipolar and bipolar sacral lateral branch RF can provide clinically meaningful pain relief when applied in carefully selected patients. The COBRA-SIJ trial is poised to refine these considerations by providing high-quality comparative data on efficacy, durability, safety, and resource utilization over a two-year horizon.
Sources (Bibliography)
- Conger A, McCormick Z, Kendall R, Wagner G, Burnham T, et al. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blind, Randomized, Comparative Trial. Protocol Version 3.0, 03 January 2023.
- Conger A. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blinded, Randomized, Comparative Trial. Clinical Trial Agreement. 2021.
- Conger A. COBRA-SIJ RCT Consent. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blinded, Randomized, Comparative Trial. Version 2, 14 September 2022.
- Conger A. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blinded, Randomized, Comparative Trial. Application Form for an Investigational Testing Authorization, Protocol Version 6.0, 11 March 2024.
- Stratus Medical. Press Release – Study to Measure Radiofrequency Ablation Outcomes for Sacroiliac Joint Pain with Nimbus. 03 March 2023.